GLP-1 & Incretin Science

The Complication That Hides Behind a Normal Glucose

UKPWritten and published by UK Peptides4 min readUpdated 3 cited sources

The short answer

Euglycaemic ketoacidosis is a metabolic acidosis driven by ketone accumulation without the marked hyperglycaemia that normally prompts the diagnosis. Because glucose looks near-normal, the condition can be missed. Both semaglutide and tirzepatide show disproportionality signals for ketoacidosis in non-diabetic patients.

Key facts

Defining feature
Ketoacidosis with glucose below the usual diagnostic threshold
Why it is missed
Glucose, the usual trigger for testing, appears reassuring
Population studied
Non-diabetic patients using these agents for obesity
Semaglutide signal
ROR 3.15 (95% CI 2.78-3.56); PRR 3.14 (2.78-3.54)
Tirzepatide signal
ROR 1.22 (95% CI 1.06-1.39); PRR 1.21 (1.06-1.39)
Reported cases
261 semaglutide, 209 tirzepatide
Hospitalisation
74.3% semaglutide, 71.3% tirzepatide
Database
FAERS, January 2021 to December 2025, 7,349,591 deduplicated reports

What ketoacidosis is, and what makes it euglycaemic

Ketoacidosis is an accumulation of ketone bodies sufficient to lower blood pH. It arises when the body shifts heavily toward fat oxidation for fuel and ketogenesis outruns the capacity to use or clear ketones. In the classical diabetic presentation, insulin deficiency drives both unrestrained ketogenesis and unrestrained hepatic glucose output, so ketosis and marked hyperglycaemia arrive together and the high glucose is what prompts the diagnostic test. Euglycaemic ketoacidosis is the same acidosis without the high glucose. The ketogenesis is present; the hyperglycaemia is not, because glucose production is suppressed or glucose is being lost or simply not being consumed.

Why the missing hyperglycaemia is the dangerous part

Clinical pathways are built around signals. A presentation of nausea, vomiting and abdominal pain with a glucose of 28 mmol/L triggers an immediate cascade of tests. The same presentation with a glucose of 7 mmol/L does not, because the number that usually raises the alarm is normal. Unless someone measures ketones or a blood gas, the acidosis is invisible. That is the entire clinical significance of the euglycaemic qualifier: it does not describe a milder illness, it describes an illness with its most recognisable sign removed.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

This class reduces energy intake substantially and reliably (that is what it is for), and it delays gastric emptying, which reduces carbohydrate delivery further. Sustained low carbohydrate intake shifts substrate use toward fat oxidation and raises ketone production, which is ordinary physiology and normally self-limiting. The concern is what happens when that baseline shift meets an additional stress: an intercurrent illness, vomiting, a period of not eating, surgery, or a very low carbohydrate diet adopted alongside treatment. Plausibility is not proof, and none of the data described here demonstrates causation. But the mechanism is not exotic, which is a reason to take the reporting signal seriously rather than dismiss it as noise.

What the pharmacovigilance data actually shows

Makhmutov and Qureshi analysed FAERS from January 2021 to December 2025. After deduplication, 7,349,591 unique reports were available; among non-diabetic patients they identified 48,082 semaglutide and 98,295 tirzepatide reports. Ketoacidosis appeared in 261 semaglutide cases and 209 tirzepatide cases. Semaglutide's reporting odds ratio was 3.15 (95% CI 2.78 to 3.56) and tirzepatide's was 1.22 (95% CI 1.06 to 1.39), both distinguishable from one. Hospitalisation was required in 74.3% and 71.3% of the reported cases respectively. That last figure is the one that carries the most weight: whatever the frequency, the cases that reach a report are mostly cases serious enough to require admission.

What these numbers cannot tell you

They cannot tell you how often this happens. A disproportionality analysis has no denominator of exposed people, so 261 cases is a count of reports and not an incidence. They cannot establish causation, because reports are voluntary, unverified and subject to attribution. And the difference between the two drugs' ratios should not be read as a difference in risk, because the two agents were approved at different times, have different exposure volumes and different reporting histories. The one thing the analysis does establish is that the pairing occurs more often than the background pattern predicts for both drugs, which is a reason for the question to be studied with a proper denominator.

Where this leaves a reader

With a documented signal, a plausible mechanism, and no measurement of frequency. That is an ordinary and uncomfortable position in drug safety, and it is where most safety questions sit for several years after a drug's launch. Semaglutide and tirzepatide are licensed medicines. Nothing supplied on this site is a version of them, an alternative to them, or anything a person should be taking, and any question about symptoms while using a licensed medicine belongs with the prescribing clinician, not a reference article.

Frequently asked questions

Does this mean these drugs cause ketoacidosis?

It means reports pairing them appear more often than the background pattern predicts, in a system that cannot establish causation. A properly designed cohort study is what would answer the question, and the signal is the reason to run one.

Why would non-diabetic patients get ketoacidosis at all?

Ketoacidosis is not exclusive to diabetes. Prolonged fasting, alcohol, and severe illness can all produce it. The relevant feature of this population is sustained large reductions in energy intake, which shifts fuel use toward fat oxidation: the same direction, from a different cause.

Is one drug safer than the other on this?

The reported ratios differ, but the two drugs differ in how long they have been marketed, how many people take them and how much attention each has had, all of which affect reporting independently of risk. A ratio difference in a spontaneous reporting database is not a risk difference.

Is this a new finding?

The clinical entity is long established, most familiar in the context of SGLT2 inhibitors, where it is a recognised and labelled concern. What is newer is the systematic comparison of these two incretin agents in a non-diabetic obesity population, which had not been done directly before this analysis.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.